BlueLight Therapeutics leverages a proprietary, structure-based discovery platform to develop novel therapeutic molecules against challenging, high-value drug targets. We have a passionate, experienced team backed by high-quality investors.

The Management Team

Ariel G. Notcovich is an accomplished life science executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his graduate studies in Physics at the Technion-Israel Institute of Technology and served as its CTO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories.

Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.

Mark Gallop, PhD is CSO at BlueLight. Mark came to the company from 5AM Ventures, which he joined as an Executive-in-Residence in June 2018. Previously, Dr. Gallop served as the founding Chief Scientific Officer at Nurix, Inc., a venture-backed discovery company formed to explore drug development targeting ubiquitin ligase enzymes, with therapeutic applications spanning oncology, immunology, inflammation and immuno-oncology. Prior to joining Nurix, Dr. Gallop co-founded XenoPort, Inc. and served as Senior Vice President of Research. While there, his team discovered Horizant™, an FDA approved prodrug of gabapentin used for the treatment of restless legs syndrome and neuropathic pain. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax.

Dr. Gallop is an inventor on more than 100 issued or pending U.S. and PCT patents and the author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry. After undergraduate studies in New Zealand, Dr. Gallop obtained his Ph.D. degree in Inorganic Chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

Mira Chaurushiya, PhD is CBO at BlueLight. Mira came to the company from 5AM Ventures, which she joined in 2015 as an Associate and was promoted to Principal in 2018. Previously, Dr. Chaurushiya worked at Genentech where she was a Postdoctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells. Prior to Genentech, she completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others.

In addition, she is a Fellow of the Society of Kauffman Fellows and serves on the Board of Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists. Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College.

Anjanabha Saha, PhD leads drug discovery efforts at BlueLight as VP, Discovery. He came to the company from 5AM Ventures, which he joined as an Executive-in-Residence in August 2018. Previously, Dr. Saha was at Nurix, Inc. where he built and headed the Lead Discovery department. There his team helped discover and progress first-in-class small molecule modulators of ubiquitin E3 ligases in the therapeutic areas of oncology, immuno-oncology and inflammation. Prior to Nurix, Dr. Saha was Director of Biology at Proteostasis Therapeutics where he led discovery efforts in the area of protein homeostasis. Previously, he was an Investigator within Cancer Research at GlaxoSmithKline.

Dr. Saha did his undergraduate in India from IIT-Delhi and followed by Ph.D. in Biochemistry working on chromatin biology with Prof. Bradley Cairns at University of Utah. He completed postdoctoral training as a Leukemia and Lymphoma Society fellow working on ubiquitin E3 ligases with Prof. Raymond Deshaies at Caltech. Dr. Saha’s work has been published in Cell, Molecular Cell and Nature journals, among others.

Board of Directors



Learn More



Learn More



Learn More



Learn More



Learn More

Our Investors

Our investors include 5AM Ventures, Pfizer Ventures, and Alexandria Venture Investments.

Career Opportunities

  • Scientist/Sr Scientist

    We are seeking a talented and highly-motivated Scientist/Sr. Scientist to join our collaborative discovery team to support small-molecule hit discovery using…

    Read More
  • Research Associate/Sr Research Associate

    We are seeking a talented and highly-motivated Research Associate/Sr. Research Associate to join our collaborative discovery team to support small-molecule hit discovery using…

    Read More

Contact Us

Get In Touch

If you are interested in working with us, please get in touch.


170 Harbor Way #100
South San Francisco, CA 94080


(650) 871-8716

This site is in no way affiliated with or endorsed by specified business. It exists as a compendium of supporting information intended for informational purposes only. If you want to buy this website, please don't hesitate to contact us via e-mail: domain (dot) sales (dot) org @ gmail (dot) com or you can find and buy it on Afternic domain auctions.